

CURRICULUM VITAE

NAME - LAST NAME

FOTIOS - LOUPAKIS



PERSONAL DATA

Date of birth: January 25th, 1979
Place of birth: Pisa, Italy
Citizenship: Italian
Work address: U.O. Oncologia 1
Istituto Oncologico Veneto
Via Gattamelata, 64 - 35128 Padova, ITALY
E-mail: fotios.loupakis@ioveneto.it

EDUCATION and POST-GRADUATE TRAINING

<i>M.D. Degree (M.D.)</i>	University of Pisa, Italy	10/08/2003
<i>Master of Science in Clinical Trials (M.S.)</i>	University of Pisa, Italy	12/31/2005
<i>Specialty in Oncology</i>	Department of Oncology University of Pisa, Italy	10/30/2007
<i>Research Doctorate in Health Biotechnologies (Ph.D.)</i>	Department of Oncology University of Pisa, Italy	06/15/2011

POSITIONS HELD

<i>Fellow</i>	General Hospital of Livorno Azienda USL6 Livorno, Italy	06/15/2004
<i>Medical Oncologist</i>	General Hospital of Livorno Azienda USL6 Livorno, Italy	11/17/2008
<i>Medical Oncologist</i>	University Hospital Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy	03/02/2009- 14/06/2016
<i>Assistant Professor</i>	Department of Oncology University of Pisa, Italy	01/01/2010- 14/06/2016
<i>Research Fellow</i>	University of Southern California Keck School of Medicine, Los Angeles, CA – United States	01/07/2011- 01/31/2012

*Coordinator
Colorectal Cancer
Multidisciplinary Team*

University Hospital
Azienda Ospedaliero-Universitaria Pisana,
Pisa, Italy

05/30/2012-
14/06/2016

*Coordinator
Trials Office*

University Hospital
Azienda Ospedaliero-Universitaria Pisana,
Pisa, Italy

01/06/2012-
14/06/2016

Medical Oncologist

Istituto Oncologico Veneto, IRCCS
Padua, Italy

since
15/06/2016

SCIENTIFIC PUBLICATIONS PEER REVIEWED JOURNALS WITH IMPACT FACTOR

N	Title - Authors - Journal	Year	Citations	2015 IF
141.	<p>Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer.</p> <p>Marmorino F, Salvatore L, Barbara C, Allegrini G, Antonuzzo L, Masi G, Loupakis F, Borelli B, Chiara S, Banzi MC, Miraglio E, Amoroso D, Dargenio F, Bonetti A, Martignetti A, Paris M, Tomcikova D, Boni L, Falcone A, Cremolini C.</p> <p>Br J Cancer. 2017 Jan 12;116(3):318-323. PMID: 28081548.</p>	2017	NA	5.569
140.	<p>Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer.</p> <p>Pasqualetti F, Montrone S, Vivaldi C, Zani M, Fedele D, Fornaro L, Pasqualetti G, Salvatore L, Manfredi B, Laliscia C, Coraggio G, Gonnelli A, Loupakis F, Masi G, Sainato A, Monzani F, Falcone A, Paia F.</p> <p>Anticancer Res. 2017 Jan;37(1):315-319. PMID: 28011508.</p>	2017	NA	1.895
139.	<p>Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.</p> <p>Cremolini C, Casagrande M, Loupakis F, Aprile G, Bergamo F, Masi G, Moretto R R, Pietrantonio F, Marmorino F, Zucchelli G, Tomasello G, Tonini G, Allegrini G, Granetto C, Ferrari L, Urbani L, Cillo U, Pilati P, Sensi E, Pellegrinelli A, Milione M, Fontanini G, Falcone A.</p> <p>Eur J Cancer. 2016 Dec 13. PMID: 27986363.</p>	2016	NA	5.417
138.	<p>Estimating 12-weeks death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram.</p> <p>Pietrantonio F, Miceli R, Rimassa L, Lonardi S, Aprile G, Mennitto A, Marmorino F, Bozzarelli S, Antonuzzo L, Tamburini E, Morano F, Rossini D, Battaglin F, Baretta M, Berenato R, Formica V, Mosconi S, Petrelli F, Ghidini M, Loupakis F, Spada D, Cinieri S, Beretta G, Falcone A, de Braud F, Cremolini C.</p> <p>Ann Oncol. 2016 Nov 17. PMID: 27864220.</p>	2016	NA	9.269
137.	<p>Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis.</p> <p>Cremolini C, Antoniotti C, Pietrantonio F, Berenato R, Tampellini M, Baratelli C, Salvatore L, Marmorino F, Borelli B, Nichetti F, Bironzo P, Sonetto C, Bartolomeo MD, de</p>	2016	NA	4.245

Braud F, **Loupakis F**, Falcone A, Maio MD.
 Cancer Res Treat. 2016 Nov 15.
 PMID: 27857020.

- | | | | | |
|------|--|------|----|--------|
| 136. | Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients.
Paolicchi E, Vivaldi C, De Gregorio V, Crea F, Fornaro L, Masi G, Loupakis F , Graziano F, Ronzoni M, Ricci V, Falcone A, Danesi R.
Oncology. 2016 Aug 31.
PMID: 27577551. | 2016 | NA | 2.152 |
| 135. | CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy.
Matsusaka S, Cao S, Hanna DL, Sunakawa Y, Ueno M, Mizunuma N, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Stremitzer S, Yamauchi S, Parekh A, Okazaki S, Berger MD, El-Khoueiry R, Mendez A, Ichikawa W, Loupakis F , Lenz HJ.
Pharmacogenomics J. 2016 Aug 9.
PMID: 27503580. | 2016 | NA | 4.229 |
| 134. | Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.
Moretto R, Cremolini C, Rossini D, Pietrantonio F, Battaglin F, Mennitto A, Bergamo F, Loupakis F , Marmorino F, Berenato R, Marsico VA, Caporale M, Antoniotti C, Masi G, Salvatore L, Borelli B, Fontanini G, Lonardi S, De Braud F, Falcone A.
Oncologist. 2016 Jul 5.
PMID: 27382031. | 2016 | NA | 4.865 |
| 133. | CDX2 as a Prognostic Biomarker in Colon Cancer.
Schirripa M, Loupakis F , Lenz HJ.
N Engl J Med. 2016 Jun 2;374(22):2183
PMID: 27248629. | 2016 | NA | 55.873 |
| 132. | Clinical significance of TLR1 1602S polymorphism for patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab.
Okazaki S, Loupakis F , Stintzing S, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y, Stremitzer S, Matsusaka S, Berger MD, Parekh A, West JD, Miyamoto Y, Suenaga M, Schirripa M, Cremolini C, Falcone A, Heinemann V, DePaolo RW, Lenz HJ.
Mol Cancer Ther. 2016 May 11
PMID: 27196764. | 2016 | NA | 5.683 |
| 131. | Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from | 2016 | NA | 9.269 |

the lab.

Sartore-Bianchi A, **Loupakis F**, Argilés G, Prager GW.

Ann Oncol. 2016 May 6.

PMID: 27154421.

- | | | | | |
|------|---|------|----|-------|
| 130. | Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies.
Aprile G, Ferrari L, Cremolini C, Bergamo F, Fontanella C, Battaglin F, Rihawi K, Lonardi S, Loupakis F , Scartozzi M.
Expert Rev Clin Pharmacol. 2016 May 5.
PMID: 27149032. | 2016 | NA | 2.180 |
| 129. | Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients.
Giampieri R, Salvatore L, Del Prete M, Prochilo T, D'Anzeo M, Loretelli C, Loupakis F , Aprile G, Maccaroni E, Andrikou K, Bianconi M, Bittoni A, Faloppi L, Demurtas L, Montironi R, Scarpelli M, Falcone A, Zaniboni A, Scartozzi M, Cascinu S.
Sci Rep. 2016 Apr 27;6:25195. doi: 10.1038/srep25195.
PMID: 27117754. | 2016 | NA | 5.578 |
| 128. | Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab.
Falvella FS, Cremolini C, Miceli R, Nichetti F, Cheli S, Antoniotti C, Infante G, Martinetti A, Marmorino F, Sottotetti E, Berenato R, Caporale M, Colombo A, de Braud F, Di Bartolomeo M, Clementi E, Loupakis F , Pietrantonio F.
Pharmacogenomics J. 2016 Mar 22. doi: 10.1038/tpj.2016.22. [Epub ahead of print]
PMID: 27001121. | 2016 | NA | 4.229 |
| 127. | Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer.
Graziano F, Ruzzo A, Giacomini E, Ricciardi T, Aprile G, Loupakis F , Lorenzini P, Ongaro E, Zoratto F, Catalano V, Sarti D, Rulli E, Cremolini C, De Nictolis M, De Maglio G, Falcone A, Fiorentini G, Magnani M.
Pharmacogenomics J. 2016 Mar 1.
PMID: 26927284. | 2016 | NA | 4.229 |
| 126. | FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
Cremolini C, Loupakis F , Masi G, Lonardi S, Granetto C, | 2016 | NA | 9.269 |

- Mancini ML, Chiara S, Moretto R, Rossini D, Vitello S, Allegrini G, Tonini G, Bergamo F, Tomasello G, Ronzoni M, Buonadonna A, Bustreo S, Barbara C, Boni L, Falcone A.
Ann Oncol. 2016 Feb 9.
PMID: 26861604.
125. Prognostic Impact of IL-6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy. 2016 NA 8.722
Matsusaka S, Hanna DL, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y, Okazaki S, Berger MD, Miyamoto Y, Parekh A, Stintzing S, **Loupakis F**, Lenz HJ.
Clin Cancer Res. 2016 Feb 2.
PMID: 26839145.
124. A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer. 2015 NA 4.000
Loupakis F, Stein A, Ychou M, Hermann F, Salud A, Österlund P.
Target Oncol. 2015 Dec 19.
PMID: 26687849.
123. TRIBE study: are all three cytotoxic drugs crucial? - Authors' reply. 2015 NA 24.690
Loupakis F, Cremolini C, Rossini D, Falcone A.
Lancet Oncol. 2015 Dec;16(16):e578-9. doi: 10.1016/S1470-2045(15)00416-7. No abstract available.
PMID: 26678196.
122. Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. 2015 NA 5.569
Loupakis F, Moretto R, Aprile G, Muntoni M, Cremolini C, Iacono D, Casagrande M, Ferrari L, Salvatore L, Schirripa M, Rossini D, De Maglio G, Fasola G, Calvetti L, Pilotto S, Carbognin L, Fontanini G, Tortora G, Falcone A, Sperduti I, Bria E.
Br J Cancer. 2015 Nov 17.
PMID: 26575603.
121. Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer. 2015 NA 3.362
Fornaro L, Faviana P, De Gregorio V, Vivaldi C, Paolicchi E, Masi G, **Loupakis F**, Sensi E, Lupi C, Fontanini G, Wang Y, Danesi R, Falcone A, Crea F.
BMC Cancer. 2015 Nov 9;15:874.
PMID: 26553291.
120. TAS-102 for the treatment of metastatic colorectal cancer. 2015 NA 2.249
Salvatore L, Rossini D, Moretto R, Cremolini C, Schirripa M, Antoniotti C, Marmorino F, **Loupakis F**, Falcone A, Masi G.

Expert Rev Anticancer Ther. 2015 Oct 28:1-10.
PMID: 26509228.

- | | | | | |
|------|--|------|----|--------|
| 119. | Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.

Renfro LA, Loupakis F , Adams RA, Seymour MT, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Falcone A, Tebbutt NC, Punt CJ, Hecht JR, Bokemeyer C, Van Cutsem E, Goldberg RM, Saltz LB, de Gramont A, Sargent DJ, Lenz HJ.

J Clin Oncol. 2015 Oct 26.
PMID: 26503203. | 2015 | NA | 18.428 |
| 118. | Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.

Valforta E, Martino C, Sartore-Bianchi A, Penault-Llorca F, Viale G, Risio M, Rugge M, Grigioni W, Bencardino K, Lonardi S, Zagonel V, Leone F, Noe J, Ciardiello F, Pinto C, Labianca R, Mosconi S, Graiff C, Aprile G, Frau B, Garufi C, Loupakis F , Racca P, Tonini G, Lauricella C, Veronese S, Truini M, Siena S, Marsoni S, Gambacorta M.

Mod Pathol. 2015 Oct 9. [Epub ahead of print]
PMID: 26449765. | 2015 | NA | 6.187 |
| 117. | Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope.

Pietrantonio F, Cremolini C, Aprile G, Lonardi S, Orlandi A, Mennitto A, Berenato R, Antoniotti C, Casagrande M, Marsico V, Marmorino F, Cardellino GG, Bergamo F, Tomasello G, Formica V, Longarini R, Giommoni E, Caporale M, Di Bartolomeo M, Loupakis F , de Braud F.

Oncologist. 2015 Oct 7. [Epub ahead of print]
PMID: 26446234. | 2015 | NA | 4.865 |
| 116. | TAS-102, a novel antitumor agent: A review of the mechanism of action.

Lenz HJ, Stintzing S, Loupakis F .

Cancer Treat Rev. 2015 Jun 6. [Epub ahead of print] Review.
PMID: 26428513. | 2015 | NA | 7.588 |
| 115. | Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: Results from TRIBE and FIRE3 trials.

Sunakawa Y, Stintzing S, Cao S, Heinemann V, Cremolini C, Falcone A, Yang D, Zhang W, Ning Y, Stremitzer S, Matsusaka S, Yamauchi S, Parekh A, Okazaki S, Berger MD, Graver S, Mendez A, Scherer SJ, Loupakis F , Lenz HJ. | 2015 | NA | 9.269 |

Ann Oncol. 2015 Sep 28.
PMID 26416897.

- | | | | | |
|------|--|------|----|--------|
| 114. | Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.
Vincenzi B, Cremolini C, Sartore-Bianchi A, Russo A, Mannavola F, Perrone G, Pantano F, Loupakis F , Rossini D, Ongaro E, Bonazzina E, Dell'Aquila E, Imperatori M, Zoccoli A, Bronte G, De Maglio G, Fontanini G, Natoli C, Falcone A, Santini D, Onetti-Muda A, Siena S, Tonini G, Aprile G.
Oncotarget. 2015 Aug 19.
PMID 26384309. | 2015 | NA | 6.359 |
| 113. | Phase II study of single agent cetuximab in KRAS G13D mutant metastatic colorectal cancer.
Schirripa M, Loupakis F , Lonardi S, Cremolini C, Bergamo F, Zagonel V, Falcone A.
Ann Oncol. 2015 Sep 14. pii: mdv385. [Epub ahead of print] No abstract available.
PMID 26371285. | 2015 | NA | 9.269 |
| 112. | BRAF-mutated metastatic colorectal cancer between past and future.
Cremolini C, Di Maio M, Petrelli F, Berenato R, Loupakis F , Pietrantonio F.
Br J Cancer. 2015 Sep 10.
PMID 26355234. | 2015 | NA | 5.569 |
| 111. | FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Cremolini C, Loupakis F , Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Carlomagno C, Allegrini G, Chiara S, D'Amico M, Granetto C, Cazzaniga M, Boni L, Fontanini G, Falcone A.
Lancet Oncol. 2015 Aug 28. [Epub ahead of print]
PMID: 26338525. | 2015 | 0 | 24.690 |
| 110. | Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management.
Del Prete MD, Giampieri R, Loupakis F , Prochilo T, Salvatore L, Faloppi L, Bianconi M, Bittoni A, Aprile G, Zaniboni A, Falcone A, Scartozzi M, Cascinu S.
Oncotarget. 2015 Aug 17. [Epub ahead of print]
PMID: 26334693. | 2015 | 0 | 6.359 |
| 109. | Response.
Cremolini C, Loupakis F , Lenz HJ. | 2015 | 0 | 12.583 |

J Natl Cancer Inst. 2015 Aug 1;107(10).
PMID: 26232792.

- | | | | | |
|------|---|------|---|--------|
| 108. | First-line chemotherapy for mCRC-a review and evidence-based algorithm.
Cremolini C, Schirripa M, Antoniotti C, Moretto R, Salvatore L, Masi G, Falcone A, Loupakis F .
Nat Rev Clin Oncol. 2015 Jul 28. Review.
PMID: 26215044. | 2015 | 0 | 14.180 |
| 107. | Polymorphisms in genes involved in EGFR-turnover are predictive for cetuximab efficacy in colorectal cancer.
Stintzing S, Zhang W, Heinemann V, Neureiter D, Kemmerling R, Kirchner T, Jung A, Folwaczny M, Yang D, Ning Y, Sebio A, Stremitzer S, Sunakawa Y, Matsusaka S, Yamauchi S, Loupakis F , Cremolini C, Falcone A, Lenz HJ.
Mol Cancer Ther. 2015 Jul 23.
PMID: 26206335. | 2015 | 0 | 5.683 |
| 106. | Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology.
Aurilio G, Gori S, Nolè F, Pruneri G, Coati F, Torri V, Lunardi G, Atzori F, Verde N, Banna GL, Rossi A, Mastro LD, Fabio FD, Marcon I, Gebbia V, Loupakis F , Orlando L, Ciuffreda L, Amadio P, Luppi G, Redana S, Filippelli G, Gentile A, Collovà E.
Tumori. 2015 Jul 2;0(0):0.
PMID: 26166216. | 2015 | 0 | 1.269 |
| 105. | BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.
Cremolini C, Di Bartolomeo M, Amatu A, Antoniotti C, Moretto R, Berenato R, Perrone F, Tamborini E, Aprile G, Lonardi S, Sartore-Bianchi A, Fontanini G, Milione M, Lauricella C, Siena S, Falcone A, de Braud F, Loupakis F , Pietrantonio F.
Ann Oncol. 2015 Jul 7. pii: mdv290. [Epub ahead of print]
PMID: 26153495. | 2015 | 0 | 9.269 |
| 104. | First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis.
Pietrantonio F, Cremolini C, Petrelli F, Di Bartolomeo M, Loupakis F , Maggi C, Antoniotti C, de Braud F, Falcone A, Iacovelli R.
Crit Rev Oncol Hematol. 2015 Jun 5.
PMID:26088456. | 2015 | 0 | 4.027 |
| 103. | Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.
Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu | 2015 | 0 | 27.363 |

A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, **Loupakis F**, Siena S, Sartore-Bianchi A, Bardelli A.

Nat Med. 2015 Jun 1.

PMID: 26030179.

- | | | | | |
|------|---|------|---|--------|
| 102. | BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection.
Schirripa M, Bergamo F, Cremolini C, Casagrande M, Lonardi S, Aprile G, Yang D, Marmorino F, Pasquini G, Sensi E, Lupi C, De Maglio G, Borrelli N, Pizzolitto S, Fasola G, Bertorelle R, Rugge M, Fontanini G, Zagonel V, Loupakis F , Falcone A.
Br J Cancer. 2015 May 5.
PMID: 25942399. | 2015 | 0 | 5.569 |
| 101. | Bevacizumab and First-line Chemotherapy for Older Patients with Advanced Colorectal Cancer: Final Results of a Community-based Observational Italian Study.
Lutrino SE, Bergamo F, Schirripa M, Rosati G, Avallone A, Giampieri R, Cordio S, Berretta M, Llimpe FR, Pisa FE, Lonardi S, Loupakis F , Fasola G, Aprile G.
Anticancer Res. 2015 Apr;35(4):2391-9.
PMID: 25862905. | 2015 | 0 | 1.826 |
| 100. | Primary tumor location as a prognostic factor in metastatic colorectal cancer.
Loupakis F , Yang D, Yau L, Feng S, Cremolini C, Zhang W, Maus MK, Antoniotti C, Langer C, Scherer SJ, Müller T, Hurwitz HI, Saltz L, Falcone A, Lenz HJ.
J Natl Cancer Inst. 2015 Feb 24;107(3).
PMID: 25713148 | 2015 | 1 | 12.583 |
| 99. | Early Tumor Shrinkage and Depth of Response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.
Cremolini C, Loupakis F , Antoniotti C, Lonardi S, Masi G, Salvatore L, Cortesi E, Tomasello G, Spadi R, Zaniboni A, Tonini G, Barone C, Vitello S, Longarini R, Bonetti A, D'Amico M, Di Donato S, Granetto C, Boni L, Falcone A.
Ann Oncol. 2015 Feb 23.
PMID: 25712456 | 2015 | 0 | 9.269 |
| 98. | Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.
Masi G, Salvatore L, Boni L, Loupakis F , Cremolini C, Fornaro L, Schirripa M, Cupini S, Barbara C, Safina V, | 2015 | 0 | 9.269 |

- Granetto C, Fea E, Antonuzzo L, Boni C, Allegrini G, Chiara S, Amoroso D, Bonetti A, Falcone A; on behalf of the BEBYP Study Investigators.
Ann Oncol. 2015 Jan 18.
PMID: 25600568
97. FOLFOXIRI and bevacizumab for metastatic colorectal cancer. 2015 0 55.873
Cremolini C, **Loupakis F**, Falcone A.
N Engl J Med. 2015 Jan 15;372(3):291-2.
PMID: 25587960
96. Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. 2015 0 4.229
Maus MK, Hanna DL, Stephens CL, Astrow SH, Yang D, Grimminger PP, **Loupakis F**, Hsiang JH, Zeger G, Wakatsuki T, Barzi A, Lenz HJ.
Pharmacogenomics J. 2014 Dec 23.
PMID: 25532759
95. Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer. 2015 0 5.513
Bohanes P, Yang D, **Loupakis F**, LaBonte MJ, Gerger A, Ning Y, Lenz C, Lenz F, Wakatsuki T, Zhang W, Benhaim L, El-Khoueiry A, El-Khoueiry R, Lenz HJ.
Pharmacogenomics J. 2014 Dec 9.
PMID: 25487679
94. Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. 2015 0 3.743
Silvestris N, Scartozzi M, Graziano G, Santini D, Lorusso V, Maiello E, Barni S, Cinieri S, **Loupakis F**, Pisconti S, Brunetti AE, Palasciano G, Palmieri VO, Del Prete M, Dell'Aquila E, Latiano TP, Petrelli F, Lutrino S, Rossini D, Giampieri R, Lotesoriere C, Cascinu S.
Expert Opin Biol Ther. 2015 Feb;15(2):155-62.
PMID: 25411089
93. Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. 2014 0 3.218
Silvestris N, Vincenzi B, Brunetti AE, **Loupakis F**, Dell'Aquila E, Russo A, Scartozzi M, Giampieri R, Cascinu S, Lorusso V, Tonini G, Falcone A, Santini D.
Pharmacogenomics. 2014 Sep;15(13):1701-15.
PMID: 25410895
92. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. 2014 13 55.873
Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V,

Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A.
N Engl J Med. 2014 Oct 23;371(17):1609-18.
 PMID: 25337750

- | | | | | |
|-----|--|------|---|--------|
| 91. | <p>Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERα-positive advanced breast cancer.</p> <p>Benhaim L, Zhang W, Wakatsuki T, Yang D, Gerger A, Bohanes P, Paez D, Loupakis F, LaBonte MJ, Ning Y, El-Khoueiry R, Ladner R, Wilson P, Zhang H, Giamas G, Stebbing J, Lenz HJ.
 <i>Pharmacogenomics J.</i> 2014 Oct 7.
 PMID: 25287073</p> | 2014 | 0 | 4.229 |
| 90. | <p>Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer.</p> <p>Volz NB, Stintzing S, Zhang W, Yang D, Ning Y, Wakatsuki T, El-Khoueiry RE, Li JE, Kardosh A, Loupakis F, Cremolini C, Falcone A, Scherer SJ, Lenz HJ.
 <i>Pharmacogenomics J.</i> 2014 Jul 29.
 PMID: 25069475</p> | 2014 | 1 | 4.229 |
| 89. | <p>FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study.</p> <p>Geva R, Vecchione L, Kalogeras KT, Vittrup Jensen B, Lenz HJ, Yoshino T, Paez D, Montagut C, Souglakos J, Cappuzzo F, Cervantes A, Frattini M, Fountzilas G, Johansen JS, Høgdall EV, Zhang W, Yang D, Yamazaki K, Nishina T, Papamichael D, Vincenzi B, Macarulla T, Loupakis F, De Schutter J, Spindler KL, Pfeiffer P, Ciardiello F, Piessevaux H, Tejpar S.
 <i>Gut.</i> 2014 Jul 10.
 PMID: 25011934</p> | 2014 | 0 | 14.660 |
| 88. | <p>Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.</p> <p>Schirripa M, Cremolini C, Loupakis F, Morvillo M, Bergamo F, Zoratto F, Salvatore L, Antoniotti C, Marmorino F, Sensi E, Lupi C, Fontanini G, Gregorio VD, Giannini R, Basolo F, Masi G, Falcone A.
 <i>Int J Cancer.</i> 2014 May 8.
 PMID: 24806288</p> | 2014 | 1 | 5.085 |
| 87. | <p>KRAS and BRAF genotyping of synchronous colorectal carcinomas.</p> <p>Giannini R, Lupi C, Loupakis F, Servadio A, Cremolini C, Sensi E, Chiarugi M, Antoniotti C, Basolo F, Falcone A, Fontanini G.</p> | 2014 | 0 | 1.554 |

- Oncol Lett. 2014 May;7(5):1532-1536. Epub 2014 Feb 21.
PMID: 24765171
86. Biomarkers and response to bevacizumab. 2014 1 8.722
Cremolini C, **Loupakis F**, Bocci G, Falcone A.
Clin Cancer Res. 2014 Feb 15;20(4):1056-7.
PMID: 24536076
85. Prospective study of EGFR intron 1 (CA)(n) repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients. 2014 3 4.229
Loupakis F, Antoniotti C, Cremolini C, Zhang W, Yang D, Wakatsuki T, Bohanes P, Schirripa M, Salvatore L, Masi G, Ricci V, Graziano F, Ruzzo A, Benhaim L, Marmorino F, Ning Y, El-Khoueiry R, Falcone A, Lenz HJ.
Pharmacogenomics J. 2014 Feb 11.
PMID: 24513691
84. Reply: Comment on 'Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab' 2013 0 5.569
Schirripa M, **Loupakis F**, Pollina L, Cremolini C, Pasquini G, Falcone A.
Br J Cancer. 2013 Oct 24.
PMID: 24157829
83. A perspective on the current management of advanced colorectal cancer. 2013 1 2.477
Casagrande M, Cremolini C, **Loupakis F**, Aprile G.
Future Oncol. 2013 Nov;9(11):1687-91.
PMID: 24156327
82. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. 2013 0 5.417
Loupakis F, Cremolini C, Salvatore L, Masi G, Sensi E, Schirripa M, Michelucci A, Pfanner E, Brunetti I, Lupi C, Antoniotti C, Bergamo F, Lonardi S, Zagonel V, Simi P, Fontanini G, Falcone A.
Eur J Cancer. 2013 Oct 15.
PMID: 24138831
81. Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States. 2013 0 5.683
Wakatsuki T, Labonte MJ, Bohanes PO, Zhang W, Yang D, Azuma M, Barzi A, Ning Y, **Loupakis F**, Saadat S, Volz N, Stintzing S, El-Khoueiry R, Koizumi W, Watanabe M, Shah M, Stebbing J, Giamas G, Lenz HJ.
Mol Cancer Ther. 2013 Oct;12(10):2261-72.
PMID: 23918832

80.	Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. Loupakis F , Cremolini C, Yang D, Salvatore L, Zhang W, Wakatsuki T, Bohanes P, Schirripa M, Benhaim L, Lonardi S, Antoniotti C, Aprile G, Graziano F, Ruzzo A, Lucchesi S, Ronzoni M, De Vita F, Tonini G, Falcone A, Lenz HJ. PLoS One. 2013 Jul 4;8(7):e66774. PMID: 23861747	2013	11	3.234
79.	Liquid biopsy: monitoring cancer-genetics in the blood. Crowley E, Di Nicolantonio F, Loupakis F , Bardelli A. Nat Rev Clin Oncol. 2013 Aug;10(8):472-84. PMID: 23836314	2013	65	14.180
78.	EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. Loupakis F , Cremolini C, Fioravanti A, Orlandi P, Salvatore L, Masi G, Schirripa M, Di Desidero T, Antoniotti C, Canu B, Faviana P, Sensi E, Lupi C, Fontanini G, Basolo F, Di Paolo A, Danesi R, Falcone A, Bocci G. Target Oncol. 2013 Jul 3. [Epub ahead of print] PMID: 23821377	2013	1	4.000
77.	Association of common gene variants in the WNT/ β -catenin pathway with colon cancer recurrence. Páez D, Gerger A, Zhang W, Yang D, Labonte MJ, Benhaim L, Kahn M, Lenz F, Lenz C, Ning Y, Wakatsuki T, Loupakis F , Lenz HJ. Pharmacogenomics J. 2013 Jul 2. PMID: 23817222	2013	2	3.218
76.	Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases. Brandi G, Derenzini E, Falcone A, Masi G, Loupakis F , Pietrabissa A, Pinna AD, Ercolani G, Pantaleo MA, Di Girolamo S, Grazi GL, de Rosa F, Biasco G. Clin Colorectal Cancer. 2013 Sep;12(3):188-94. PMID: 23773458	2013	2	2.813
75.	Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy. Benhaim L, Gerger A, Bohanes P, Paez D, Wakatsuki T, Yang D, Labonte MJ, Ning Y, El-Khoueiry R, Loupakis F , Zhang W, Laurent-Puig P, Lenz HJ. Pharmacogenomics J. 2013 Jun 11. PMID: 23752739	2013	4	4.229
74.	Histopathologic evaluation of liver metastases from	2013	0	5.569

colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab.

Loupakis F, Schirripa M, Caparello C, Funel N, Pollina L, Vasile E, Cremolini C, Salvatore L, Morvillo M, Antoniotti C, Marmorino F, Masi G, Falcone A.

Br J Cancer. 2013 Jun 25;108(12):2549-56.

PMID: 23703247

- | | | | | |
|-----|--|------|---|-------|
| 73. | FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).
Fornaro L, Lonardi S, Masi G, Loupakis F , Bergamo F, Salvatore L, Cremolini C, Schirripa M, Vivaldi C, Aprile G, Zaniboni A, Bracarda S, Fontanini G, Sensi E, Lupi C, Morvillo M, Zagonel V, Falcone A.
Ann Oncol. 2013 May 10.
PMID: 23666916 | 2013 | 0 | 9.269 |
| 72. | Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy.
Negri FV, Musolino A, Naldi N, Bortesi B, Missale G, Laccabue D, Zerbini A, Camisa R, Chernyschova N, Bisagni G, Loupakis F , Ruzzo A, Neri TM, Ardizzoni A.
Pharmacogenomics J. 2013 Jan 8.
PMID: 23296156 | 2013 | 1 | 4.229 |
| 71. | Caveolin-1 is a novel regulator of K-RAS-dependent migration in colon carcinogenesis.
Roy UK, Henkhaus RS, Loupakis F , Cremolini C, Gerner EW, Ignatenko NA.
Int J Cancer. 2012 Dec 22. doi: 10.1002/ijc.28001. [Epub ahead of print]
PMID: 23280667 | 2012 | 7 | 5.085 |
| 70. | Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients.
Vincenzi B, Zoccoli A, Schiavon G, Iuliani M, Pantano F, Dell'aquila E, Ratta R, Muda AO, Perrone G, Brunelli C, Correale P, Riva E, Russo A, Loupakis F , Falcone A, Santini D, Tonini G.
Eur J Cancer. 2012 Dec 21. [Epub ahead of print]
PMID: 23266047 | 2012 | 8 | 5.417 |
| 69. | Selecting the best targeted agent in first-line treatment of unresectable liver metastases from colorectal cancer: does the bench have the answers?
Benhaim L, Loupakis F , Labonte MJ, Lenz HJ.
J Hepatobiliary Pancreat Sci. 2012 Sep;19(5):528-35. | 2012 | 0 | 2.994 |

PMID: 22735932 [PubMed - in process]

- | | | | | |
|-----|--|------|----|--------|
| 68. | Influence of Sex on the Survival of Patients With Esophageal Cancer.
Bohanes P, Yang D, Chhibar RS, Labonte MJ, Winder T, Ning Y, Gerger A, Benhaim L, Paez D, Wakatsuki T, Loupakis F , El-Khoueiry R, Zhang W, Lenz HJ.
J Clin Oncol. 2012 May 14. [Epub ahead of print]
PMID: 22585694 | 2012 | 20 | 18.428 |
| 67. | High Let-7a MicroRNA Levels in KRAS-Mutated Colorectal Carcinomas May Rescue Anti-EGFR Therapy Effects in Patients with Chemotherapy-Refractory Metastatic Disease.
Ruzzo A, Graziano F, Vincenzi B, Canestrari E, Perrone G, Galluccio N, Catalano V, Loupakis F , Rabitti C, Santini D, Tonini G, Fiorentini G, Rossi D, Falcone A, Magnani M.
Oncologist. 2012 May 14 | 2012 | 20 | 4.865 |
| 66. | Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer.
Manzoni M, Mariucci S, Delfanti S, Rovati B, Ronzoni M, Loupakis F , Brugnatelli S, Tinelli C, Villa E, Falcone A, Danova M.
J Cancer Res Clin Oncol. 2012 Mar 15. [Epub ahead of print]
PMID: 22419441 | 2012 | 10 | 3.081 |
| 65. | EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle.
Fornaro L, Crea F, Masi G, Paolicchi E, Loupakis F , Graziano F, Salvatore L, Ronzoni M, Ricci V, Cremolini C, Schiripa M, Danesi R, Falcone A.
Ann Oncol. 2012 Mar 7.
PMID: 22383679 | 2012 | 0 | 9.269 |
| 64. | Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers.
Allegrini G, Di Desidero T, Barletta MT, Fioravanti A, Orlandi P, Canu B, Chericoni S, Loupakis F , Di Paolo A, Masi G, Fontana A, Lucchesi S, Arrighi G, Giusiani M, Ciarlo A, Brandi G, Danesi R, Kerbel RS, Falcone A, Bocci G.
Angiogenesis. 2012 Mar 2.
PMID: 22382585 | 2012 | 13 | 4.876 |
| 63. | The possible role of chemotherapy in antiangiogenic drug resistance.
Bocci G, Loupakis F . | 2012 | 6 | 1.074 |

Med Hypotheses. 2012 Feb 24.
PMID: 22365648

- | | | | | |
|-----|---|------|----|--------|
| 62. | "HER Majesty's a Pretty Nice Girl but She Changes From Day to Day".
Bohanes P, Loupakis F , Labonte MJ, Wakatsuki T, Lenz HJ.
J Clin Oncol. 2012 Feb 1;30(4):465-6.
PMID: 22203763 | 2012 | 2 | 18.428 |
| 61. | Cancer dormancy: a model of early dissemination and late cancer recurrence.
Páez D, Labonte MJ, Bohanes P, Zhang W, Benhanim L, Ning Y, Wakatsuki T, Loupakis F , Lenz HJ.
Clin Cancer Res. 2012 Feb 1;18(3):645-53.
PMID: 22156560 | 2012 | 30 | 8.722 |
| 60. | Analysis of HER-3, insulin growth factor-1, nuclear factor- κ B and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.
Scartozzi M, Giampieri R, Maccaroni E, Mandolesi A, Giustini L, Silva R, Zaniboni A, Biscotti T, Biagetti S, Galizia E, Loupakis F , Falcone A, Bearzi I, Cascinu S.
Ann Oncol. 2011 Nov 23.
PMID: 22112971 | 2011 | 0 | 9.269 |
| 59. | Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: Meta-analytical estimation and implications for therapeutic strategies.
Loupakis F , Cremolini C, Salvatore L, Schirripa M, Lonardi S, Vaccaro V, Cuppone F, Giannarelli D, Zagonel V, Cognetti F, Tortora G, Falcone A, Bria E.
Cancer. 2011 Aug 25.
PMID: 22009364 | 2011 | 10 | 4.889 |
| 58. | An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.
Crea F, Fornaro L, Paolicchi E, Masi G, Frumento P, Loupakis F , Salvatore L, Cremolini C, Schirripa M, Graziano F, Ronzoni M, Ricci V, Farrar WL, Falcone A, Danesi R.
Ann Oncol. 2011 Sep 16.
PMID: 21926398 | 2011 | 0 | 9.269 |
| 57. | Outcome of Second-Line Treatment After First-Line Chemotherapy With the GONO FOLFOXIRI Regimen.
Fornaro L, Vasile E, Masi G, Loupakis F , Baldi GG, Allegrini G, Salvatore L, Cremolini C, Cupini S, Cortesi E, Tuzi A, Granetto C, Brunetti IM, Ricci S, Falcone A.
Clin Colorectal Cancer. 2011 Sep 6. | 2011 | 5 | 2.813 |

PMID: 21903485

56. Bevacizumab pharmacogenetics in tumor treatment: still looking for the right pieces of the puzzle.
Bocci G, **Loupakis F**.
Pharmacogenomics. 2011 Aug;12(8):1077-80.
PMID: 21843059
55. Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer.
Loupakis F, Ruzzo A, Salvatore L, Cremolini C, Masi G, Frumento P, Schirripa M, Catalano V, Galluccio N, Canestrari E, Vincenzi B, Santini D, Bencardino K, Ricci V, Manzoni M, Danova M, Tonini G, Magnani M, Falcone A, Graziano F.
BMC Cancer. 2011 Jun 14;11:247.
PMID: 21669012
54. Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients.
Scartozzi M, Bearzi I, Mandolesi A, Giampieri R, Faloppi L, Galizia E, **Loupakis F**, Zaniboni A, Zorzi F, Biscotti T, Labianca R, Falcone A, Cascinu S.
Br J Cancer. 2011 May 10.
PMID: 21559018
53. Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer.
Catalano V, **Loupakis F**, Graziano F, Bissoni R, Torresi U, Vincenzi B, Mari D, Giordani P, Alessandrini P, Salvatore L, Fornaro L, Santini D, Baldelli AM, Rossi D, Giustini L, Silva RR, Falcone A, D'Emidio S, Rocchi M, Luzi Fedeli S.
Ann Oncol. 2011 Apr 29.
PMID: 21531784
52. PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients.
Vincenzi B, Santini D, Perrone G, Graziano F, **Loupakis F**, Schiavon G, Frezza AM, Ruzzo AM, Rizzo S, Crucitti P, Galluzzo S, Zoccoli A, Rabitti C, Muda AO, Russo A, Falcone A, Tonini G.
J Cell Physiol. 2011 Apr 18. [Epub ahead of print]
PMID: 21503888
51. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.
Loupakis F, Cremolini C, Fioravanti A, Orlandi P, Salvatore L, Masi G, Di Desidero T, Canu B, Schirripa M, Frumento P,

Di Paolo A, Danesi R, Falcone A, Bocci G.
Br J Cancer. 2011 Mar 15. [Epub ahead of print]
PMID: 21407216

- | | | | | |
|-----|--|------|----|--------|
| 50. | Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer.
Manzoni M, Rovati B, Ronzoni M, Loupakis F , Mariucci S, Ricci V, Gattoni E, Salvatore L, Tinelli C, Villa E, Danova M.
Oncology. 2011 Feb 28;79(3-4):187-196
PMID: 21358206 | 2011 | 0 | 2.422 |
| 49. | Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer.
Loupakis F , Cremolini C, Schirripa M, Masi G, Falcone A.
Expert Opin Biol Ther. 2011 Jan 27. [Epub ahead of print]
PMID: 21269235 | 2011 | 0 | 3.743 |
| 48. | Should Oncologists Be Aware in Their Clinical Practice of KRAS Molecular Analysis?
Santini D, Galluzzo S, Gaeta L, Zoccoli A, Riva E, Ruzzo A, Vincenzi B, Graziano F, Loupakis F , Falcone A, Muda AO, Tonini G.
J Clin Oncol. 2011 Jan 24.
PMID: 21263083 | 2011 | 12 | 18.428 |
| 47. | Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.
Masi G, Vasile E, Loupakis F , Cupini S, Fornaro L, Baldi G, Salvatore L, Cremolini C, Stasi I, Brunetti I, Fabbri MA, Puglisi M, Trenta P, Granetto C, Chiara S, Fioretto L, Allegrini G, Crinò L, Andreuccetti M, Falcone A.
J Natl Cancer Inst. 2011 Jan 5;103(1):21-30.
PMID: 21123833 | 2011 | 39 | 12.583 |
| 46. | Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients.
Vincenzi B, Galluzzo S, Santini D, Rocci L, Loupakis F , Correale P, Addeo R, Zoccoli A, Napolitano A, Graziano F, Ruzzo A, Falcone A, Francini G, Dicuonzo G, Tonini G.
Ann Oncol. 2010 Nov 29.
PMID: 21115601 | 2010 | 0 | 9.269 |
| 45. | Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy.
Graziano F, Ruzzo A, Canestrari E, Catalano V, Santini D, Galluccio N, Loupakis F , Alessandrini P, Spada D, Ficarelli R, Bissoni R, D'Emidio S, Vincenzi B, Angeletti S, Salvatore L, Cremolini C, Tonini G, Falcone A, Magnani M. | 2010 | 0 | 3.218 |

Pharmacogenomics. 2010 Sep;11(9):1247-56.

PMID: 20860465

- | | | | | |
|-----|--|------|-----|--------|
| 44. | Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Masi G, Loupakis F , Salvatore L, Fornaro L, Cremolini C, Cupini S, Ciarlo A, Del Monte F, Cortesi E, Amoroso D, Granetto C, Fontanini G, Sensi E, Lupi C, Andreuccetti M, Falcone A.
Lancet Oncol. 2010 Sep;11(9):845-52. Epub 2010 Aug 9.
PMID: 20702138 | 2010 | 84 | 24.690 |
| 43. | Epidermal growth factor receptor gene promoter methylation in primary colorectal tumors and corresponding metastatic sites: a new perspective for an "old" therapeutic target.
Scartozzi M, Bearzi I, Mandolesi A, Galizia E, Pierantoni C, Loupakis F , Berardi R, Zaniboni A, Quadri A, Zorzi F, Biagetti S, Loretelli C, Biscotti T, Labianca R, Masi G, Falcone A, Cascinu S.
Anal Quant Cytol Histol. 2009 Dec;31(6):417-23.
PMID: 20698358 | 2009 | 2 | 0.488 |
| 42. | Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status.
Fornaro L, Baldi GG, Masi G, Allegrini G, Loupakis F , Vasile E, Cupini S, Stasi I, Salvatore L, Cremolini C, Vincenzi B, Santini D, Tonini G, Graziano F, Ruzzo A, Canestrari E, Magnani M, Falcone A.
Crit Rev Oncol Hematol. 2010 Jul 7. | 2010 | 10 | 4.027 |
| 41. | High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice.
Santini D, Spoto C, Loupakis F , Vincenzi B, Silvestris N, Cremolini C, Canestrari E, Graziano F, Galluccio N, Salvatore L, Caraglia M, Zito FA, Colucci G, Falcone A, Tonini G, Ruzzo A.
Ann Oncol. 2010 Jul;21(7):1565.
PMID: 20573852 | 2010 | 112 | 9.269 |
| 40. | Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials.
Loupakis F , Bria E, Vaccaro V, Cuppone F, Milella M, Carlini P, Cremolini C, Salvatore L, Falcone A, Muti P, Sperduti I, Giannarelli D, Cognetti F.
J Exp Clin Cancer Res. 2010 May 26;29:58.
PMID: 20504361 | 2010 | 23 | 4.429 |

- | | | | | |
|-----|--|------|----|--------|
| 39. | <p>Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients.</p> <p>Ronzoni M, Manzoni M, Mariucci S, Loupakis F, Brugnatelli S, Bencardino K, Rovati B, Tinelli C, Falcone A, Villa E, Danova M.</p> <p>Ann Oncol. 2010 Dec;21(12):2382-9. Epub 2010 May 23.
PMID: 20497963</p> | 2010 | 0 | 9.269 |
| 38. | <p>Chemotherapy: How useful is adjuvant irinotecan in stage IV CRC?</p> <p>Loupakis F, Falcone A.</p> <p>Nat Rev Clin Oncol. 2010 Apr;7(4):190-1.
PMID: 20354542</p> | 2010 | 1 | 14.180 |
| 37. | <p>Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.</p> <p>Loupakis F, Masi G, Fornaro L, Vasile E, Allegrini G, Fontana E, Granetto C, Salvatore L, Mentuccia L, Andreuccetti M, Cortesi E, Merlano M, Cascinu S, Falcone A.</p> <p>Cancer Chemother Pharmacol. 2010 Aug;66(3):559-66. Epub 2010 Mar 17.
PMID: 20237927</p> | 2010 | 2 | 2.769 |
| 36. | <p>Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.</p> <p>Graziano F, Canestrari E, Loupakis F, Ruzzo A, Galluccio N, Santini D, Rocchi M, Vincenzi B, Salvatore L, Cremolini C, Spoto C, Catalano V, D'Emidio S, Giordani P, Tonini G, Falcone A, Magnani M.</p> <p>Pharmacogenomics J. 2010 Oct;10(5):458-64.
PMID: 20177422</p> | 2010 | 53 | 4.229 |
| 35. | <p>Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "TranslationAL"?</p> <p>Cremolini C, Loupakis F, Ruzzo A, Perrone G, Rulli E, Vincenzi B, Tonini G, Graziano F, Muda AO, Falcone A.</p> <p>J Clin Oncol. 2010 Apr 10;28(11):e173-4.
PMID: 20177018</p> | 2010 | 1 | 18.428 |
| 34. | <p>Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan.</p> <p>Scartozzi M, Mandolesi A, Giampieri R, Pierantoni C, Loupakis F, Zaniboni A, Galizia E, Giustini L, Silva RR, Bissoni R, Berardi R, Biagetti S, Menzo S, Falcone A, Bearzi</p> | 2010 | 33 | 5.085 |

I, Cascinu S.

Int J Cancer. 2010 Oct 15;127(8):1941-7.

PMID: 20099280

- | | | | | |
|-----|--|------|----|--------|
| 33. | Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients.
Loupakis F , Bocci G, Pasqualetti G, Fornaro L, Salvatore L, Cremolini C, Masi G, Danesi R, Del Tacca M, Falcone A.
Curr Cancer Drug Targets. 2010 Feb 1;10(1):37-45.
PMID: 20088795 | 2010 | 0 | 3.522 |
| 32. | Palliative treatment of unresectable metastatic colorectal cancer.
Fornaro L, Masi G, Loupakis F , Vasile E, Falcone A.
Expert Opin Pharmacother. 2010 Jan;11(1):63-77. Review.
PMID: 20001430 | 2010 | 11 | 3.534 |
| 31. | Capecitabine after gastrectomy for advanced gastric cancer: have we got the patient right?
Fornaro L, Vasile E, Masi G, Loupakis F , Caponi S, Ginocchi L, Falcone A.
Ann Oncol. 2010 Jan;21(1):181. Epub 2009 Nov 4.
PMID: 19889616 | 2010 | 0 | 9.269 |
| 30. | Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer.
Loupakis F , Cremolini C, Fontanini G, Stasi I, Salvatore L, Falcone A.
Ther Adv Med Oncol. 2009 Nov;1(3):167-81.
PMID: 21789120 | 2009 | 0 | 2.827 |
| 29. | Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine.
Masi G, Fornaro L, Cupini S, Loupakis F , Vasile E, Baldi GG, Stasi I, Salvatore L, Falcone A.
Nat Rev Clin Oncol. 2009 Nov;6(11):670-4.
PMID: 19861994 | 2009 | 0 | 14.180 |
| 28. | Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis.
Scartozzi M, Bearzi I, Mandolesi A, Pierantoni C, Loupakis F , Zaniboni A, Negri F, Quadri A, Zorzi F, Galizia E, Berardi R, Biscotti T, Labianca R, Masi G, Falcone A, Cascinu S.
BMC Cancer. 2009 Aug 27;9:303.
PMID: 19712476 | 2009 | 39 | 3.362 |

- | | | | | |
|-----|---|------|-----|--------|
| 27. | <p>KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.</p> <p>Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F. Br J Cancer. 2009 Aug 18;101(4):715-21. Epub 2009 Jul 14. PMID: 19603018</p> | 2009 | 248 | 5.569 |
| 26. | <p>Do we need biopsies of metastases for colorectal cancer patients?</p> <p>Floriani I, Santini D, Torri V, Cremolini C, Falcone A, Loupakis F. Br J Cancer. 2009 Jul 21;101(2):374-5; author reply 376. Epub 2009 Jul 7. PMID: 19584870</p> | 2009 | 0 | 5.569 |
| 25. | <p>Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients.</p> <p>Vincenzi B, Santini D, Loupakis F, Addeo R, Rojas Llimpe FL, Baldi GG, Di Fabio F, Del Prete S, Pinto C, Falcone A, Tonini G. Expert Opin Biol Ther. 2009 Aug;9(8):945-9. PMID: 19534585</p> | 2009 | 7 | 3.743 |
| 24. | <p>Chemotherapy and immunotherapy in metastatic colorectal cancer.</p> <p>Loupakis F, Di Maio M, Falcone A. N Engl J Med. 2009 May 14;360(20):2135; author reply 2135-6. PMID: 19445032</p> | 2009 | 0 | 55.873 |
| 23. | <p>A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.</p> <p>Vasile E, Masi G, Fornaro L, Cupini S, Loupakis F, Bursi S, Petrini I, Di Donato S, Brunetti IM, Ricci S, Antonuzzo A, Chiara S, Amoroso D, Andreuccetti M, Falcone A. Br J Cancer. 2009 Jun 2;100(11):1720-4. PMID: 19436300</p> | 2009 | 0 | 5.569 |
| 22. | <p>PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.</p> <p>Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G, Campani D, Floriani I, Cascinu S, Falcone A. J Clin Oncol. 2009 Jun 1;27(16):2622-9.</p> | 2009 | 229 | 18.428 |

PMID: 19398573

- | | | | | |
|-----|--|------|----|-------|
| 21. | Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy.
Catalano V, Loupakis F , Graziano F, Torresi U, Bissoni R, Mari D, Fornaro L, Baldelli AM, Giordani P, Rossi D, Alessandrini P, Giustini L, Silva RR, Falcone A, D'Emidio S, Fedeli SL.
Br J Cancer. 2009 Mar 24;100(6):881-7. Epub 2009 Mar 3.
PMID: 19259089 | 2009 | 0 | 5.569 |
| 20. | Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.
Masi G, Loupakis F , Pollina L, Vasile E, Cupini S, Ricci S, Brunetti IM, Ferraldeschi R, Naso G, Filipponi F, Pietrabissa A, Goletti O, Baldi G, Fornaro L, Andreuccetti M, Falcone A.
Ann Surg. 2009 Mar;249(3):420-5.
PMID: 19247029 | 2009 | 92 | 8.327 |
| 19. | Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer.
Graziano F, Ruzzo A, Canestrari E, Loupakis F , Santini D, Rulli E, Humar B, Galluccio N, Bissoni R, Floriani I, Maltese P, Falcone A, Tonini G, Catalano V, Fontana A, Giustini L, Masi G, Vincenzi B, Alessandrini P, Magnani M.
Pharmacogenomics J. 2009 Feb;9(1):78-84. Epub 2008 Dec 23.
PMID: 19104506 | 2009 | 0 | 4.229 |
| 18. | High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.
Santini D, Loupakis F , Vincenzi B, Floriani I, Stasi I, Canestrari E, Rulli E, Maltese PE, Andreoni F, Masi G, Graziano F, Baldi GG, Salvatore L, Russo A, Perrone G, Tommasino MR, Magnani M, Falcone A, Tonini G, Ruzzo A.
Oncologist. 2008 Dec;13(12):1270-5. Epub 2008 Dec 4.
PMID: 19056857 | 2009 | 0 | 4.865 |
| 17. | Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction.
Bocci G, Di Paolo A, Barbara C, Masi G, Fornaro L, Loupakis F , Allegrini G, Falcone A, Del Tacca M, Danesi R.
Br J Clin Pharmacol. 2009 Jan;67(1):132-4. Epub 2008 Nov 5. | 2009 | 5 | 3.878 |

- PMID: 19006547
16. Optimal approach to potentially resectable liver metastases from colorectal cancer. 2008 1 2.249
 Falcone A, Fornaro L, **Loupakis F**, Masi G, Vasile E.
 Expert Rev Anticancer Ther. 2008 Oct;8(10):1533-9. Review.
 PMID: 18925845
15. A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. 2009 7 2.769
 Fornaro L, Masi G, Bursi S, **Loupakis F**, Vasile E, Antonuzzo A, Chiara S, Pfanner E, Di Paolo A, Bocci G, Del Tacca M, Falcone A.
 Cancer Chemother Pharmacol. 2009 Apr;63(5):965-9. Epub 2008 Oct 7.
 PMID: 18839174
14. VEGF gene polymorphisms and susceptibility to colorectal cancer disease in Italian population. 2009 25 2.449
 Maltese P, Canestrari E, Ruzzo A, Graziano F, Falcone A, **Loupakis F**, Tonini G, Santini D, Magnani M.
 Int J Colorectal Dis. 2009 Feb;24(2):165-70. Epub 2008 Oct 2.
 PMID: 18830612
13. Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy. 2008 0 5.569
 Graziano F, Ruzzo A, **Loupakis F**, Santini D, Catalano V, Canestrari E, Maltese P, Bisonni R, Fornaro L, Baldi G, Masi G, Falcone A, Tonini G, Giordani P, Alessandrini P, Giustini L, Vincenzi B, Magnani M.
 Br J Cancer. 2008 Sep 2;99(5):716-21. Epub 2008 Aug 12.
 PMID: 18728661
12. First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first? 2008 9 4.466
Loupakis F, Masi G, Vasile E, Falcone A.
 Curr Opin Oncol. 2008 Jul;20(4):459-65. Review.
 PMID: 18525344
11. A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. 2008 0 5.569
 Allegrini G, Falcone A, Fioravanti A, Barletta MT, Orlandi P, **Loupakis F**, Cerri E, Masi G, Di Paolo A, Kerbel RS, Danesi R, Del Tacca M, Bocci G.
 Br J Cancer. 2008 Apr 22;98(8):1312-9. Epub 2008 Mar 25.
 PMID: 18362940

- | | | | | |
|-----|--|------|-----|--------|
| 10. | <p>Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.</p> <p>Graziano F, Ruzzo A, Loupakis F, Canestrari E, Santini D, Catalano V, Bisonni R, Torresi U, Floriani I, Schiavon G, Andreoni F, Maltese P, Rulli E, Humar B, Falcone A, Giustini L, Tonini G, Fontana A, Masi G, Magnani M.</p> <p>J Clin Oncol. 2008 Mar 20;26(9):1427-34.
PMID: 18349392</p> | 2008 | 72 | 18.428 |
| 9. | <p>Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer.</p> <p>Masi G, Vasile E, Loupakis F, Bursi S, Ricci S, Petrini I, Fontana A, Allegrini G, Falcone A.</p> <p>Clin Colorectal Cancer. 2008 Jan;7(1):7-14. Review.
PMID: 18279572</p> | 2008 | 10 | 2.813 |
| 8. | <p>EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach.</p> <p>Loupakis F, Vasile E, Santini D, Masi G, Falcone A, Graziano F.</p> <p>Pharmacogenomics. 2008 Jan;9(1):55-69. Review.
PMID: 18154448</p> | 2008 | 10 | 3.218 |
| 7. | <p>Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.</p> <p>Scartozzi M, Bearzi I, Pierantoni C, Mandolesi A, Loupakis F, Zaniboni A, Catalano V, Quadri A, Zorzi F, Berardi R, Biscotti T, Labianca R, Falcone A, Cascinu S.</p> <p>J Clin Oncol. 2007 Sep 1;25(25):3930-5.
PMID: 17761976</p> | 2007 | 74 | 18.428 |
| 6. | <p>Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy.</p> <p>Ruzzo A, Graziano F, Loupakis F, Santini D, Catalano V, Bisonni R, Ficarelli R, Fontana A, Andreoni F, Falcone A, Canestrari E, Tonini G, Mari D, Lippe P, Pizzagalli F, Schiavon G, Alessandrini P, Giustini L, Maltese P, Testa E, Menichetti ET, Magnani M.</p> <p>Pharmacogenomics J. 2008 Aug;8(4):278-88. Epub 2007 Jun 5.
PMID: 17549067</p> | 2008 | 154 | 4.229 |
| 5. | <p>Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity.</p> <p>Loupakis F, Falcone A, Masi G, Fioravanti A, Kerbel RS, Del Tacca M, Bocci G.</p> | 2007 | 35 | 18.428 |

J Clin Oncol. 2007 May 1;25(13):1816-8.

PMID: 17470880

- | | | | | |
|----|--|------|----|--------|
| 4. | Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
Ruzzo A, Graziano F, Loupakis F , Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M.
J Clin Oncol. 2007 Apr 1;25(10):1247-54.
PMID: 17401013 | 2007 | 0 | 18.428 |
| 3. | Are dose-finding studies still necessary when targeted therapy is associated with chemotherapy?
Gelibter AJ, Lonardi S, Di Segni S, Fontana A, Loupakis F , Cognetti F, Labianca R.
J Clin Oncol. 2006 Oct 1;24(28):4668-9.
PMID: 17008710 | 2006 | 0 | 18.428 |
| 2. | First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer.
Masi G, Marcucci L, Loupakis F , Cerri E, Barbara C, Bursi S, Allegrini G, Brunetti IM, Murr R, Ricci S, Cupini S, Andreuccetti M, Falcone A.
Ann Oncol. 2006 Aug;17(8):1249-54.
PMID: 16766580 | 2006 | 0 | 9.269 |
| 1. | Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer.
Masi G, Cupini S, Marcucci L, Cerri E, Loupakis F , Allegrini G, Brunetti IM, Pfanner E, Viti M, Goletti O, Filipponi F, Falcone A.
Ann Surg Oncol. 2006 Jan;13(1):58-65. Epub 2006 Jan 1.
PMID: 16372158 | 2006 | 92 | 3.930 |

Date January 17th, 2017

Personal data use authorized according to the Italian Law D.Lgs 196/03.

